Results 161 to 170 of about 3,665 (185)

Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2021
Abstract Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are caused by aberrant mechanistic Target of Rapamycin Complex 1 (mTORC1) activation due to loss of either TSC1 or TSC2 . Cytokine profiling of TSC2-deficient LAM patient-
Ji Wang, Harilaos Filippakis, Heng Du
exaly   +3 more sources

Psat1-Dependent Fluctuations in α-Ketoglutarate Affect the Timing of ESC Differentiation [PDF]

Cell Metabolism, 2016
Embryonic stem cells (ESCs) undergo coordinated epigenetic and metabolic changes to differentiate properly. However, the precise mechanisms by which these alterations are fine-tuned in the early stages of differentiation have not been identified. In this study, we demonstrate that phosphoserine aminotransferase 1 (Psat1), an Oct4/Sox2/Nanog (OSN ...
In-Young Hwang, Sojung Kwak, Sang Eun Lee   +2 more
exaly   +3 more sources

PSAT1 inhibits MTORC1 activation by preventing RRAG heterodimer formation in lung adenocarcinoma

Autophagy
The mechanistic target of rapamycin complex 1 (mTORC1) integrates environmental cues, especially amino acids, to regulate metabolism and ultimately cancer progression. Phosphoserine aminotransferase 1 (PSAT1) is a key enzyme in de novo serine synthesis and its overexpression has been reported to promote oncogenesis in various cancers.
Zhujun Cheng, Tao Zhao, Longhua Sun
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis

Oncogene, 2020
An increasing number of enzymes involved in serine biosynthesis have been identified and correlated with malignant evolution in various types of cancer. Here we showed that the overexpression of phosphoserine aminotransferase 1 (PSAT1) is widely found in lung cancer tissues compared with nontumor tissues and predicts a poorer prognosis in patients with
Yung-Chieh Chan, Yu-Chan Chang, Hsiang-Hao Chuang, Yi-Chieh Yang, Yuan-Feng Lin, Ming-Shyan Huang, Michael Hsiao, Chih-Jen Yang, Kuo-Tai Hua   +8 more
openaire   +2 more sources

Pathogenic PSAT1 Variants and Autosomal Recessive Axonal Charcot-Marie-Tooth Disease With Ichthyosis

Pediatric Neurology, 2023
Biallelic pathogenic phosphoserine aminotransferase 1 (PSAT1) variants generally cause a severe phenotype predominantly involving the central nervous system. Here, for the first time, we report two patients harboring pathogenic PSAT1 variants only manifested as polyneuropathy and ichthyosis.Two patients from unrelated families presenting with ...
Yanyu Lu, Zhiying Xie
exaly   +3 more sources

The protective effects of phosphoserine aminotransferase 1 (PSAT1) against hepatic ischemia–reperfusion injury

Journal of Cell Communication and Signaling, 2023
Hepatic ischemia-reperfusion (I/R) injury is a severe clinical syndrome, causing a profound medical and socioeconomic burden worldwide. This study aimed to explore underlying biomarkers and treatment targets in the progression of hepatic I/R injury. We screened gene expression profiles of the hepatic I/R injury from the Gene Expression Omnibus (GEO ...
Yinzhi Deng, Hesheng Luo
openaire   +2 more sources

Circ_0015756 promotes ovarian cancer progression via the miR-145–5p/PSAT1 axis

Reproductive Biology, 2022
Circular RNA (circRNA) have been shown to exert vital functions in the pathological progressions of ovarian cancer (OC). Herein, this study aimed to investigate the role and mechanisms of circ_0015756 in OC progression. Levels of circ_0015756, microRNA (miR)- 145-5p and phosphoserine aminotransferase 1 (PSAT1) were detected using quantitative real-time
Yizhen, Pan, Qianyu, Huang, Xiaodan, Peng, Shaokang, Yu, Nannan, Liu   +4 more
openaire   +2 more sources

PSAT1 gene as a biomarker for targeting triple negative breast cancer in presence of Rapamycin

Nucleosides, Nucleotides & Nucleic Acids, 2022
The Triple-Negative Breast Cancers (TNBCs) poor survival outcomes are related to not responding to hormonal therapy or targeting HER2 protein. The aim of this study was to introduce a drug among the conventional chemotherapy drugs based on the transcripts of the TNBC patients.
Mehdi Roshanian Bakhsh, Maryam Peymani, Leila Rouhi, Kamran Ghaedi   +3 more
openaire   +2 more sources

PSAT1 Suppression Drives a Targetable Serine Dependence in AML

Blood
From antifolates to asparaginase to IDH inhibitors, targeting cancer metabolism has proven useful in heme malignancies. In solid tumors, a therapy with recent momentum is depriving cancer of serine. In vivo, this is done with a serine- and glycine-free (-SG) diet, which is tolerated by mice and can slow tumor ...
Ilias Sinanidis, Panagiotis Tsakiroglou, Rebecca Foertsch, Julia Gondek, Benjamin Dubner, InYoung Choi, Bogdan Paun, Liang Zhao, Everett Stone, George Georgiou, Gabriel Ghiaur, William Brian Dalton   +11 more
openaire   +1 more source

PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation

Nature Chemical Biology
Tumor cells adapt to the inflammatory tumor microenvironment (TME) and develop resistance to immunotherapy, with ferroptosis being a major form of tumor cell death. However, the mechanisms by which tumor cells coordinate TME stimuli and their unique metabolic traits to evade ferroptosis and develop resistance to immunotherapy remain unclear.
Peixiang Zheng, Zhiqiang Hu, Yuli Shen, Lina Gu, Yuan Ouyang, Yuran Duan, Guimei Ji, Bofei Dong, Yanni Lin, Ting Wen, Qi Tian, Yueru Hou, Qimin Zhou, Xue Sun, Xiaohan Chen, Katherine L. Wang, Shudi Luo, Shiqi Wu, Yuening Sun, Min Li, Liwei Xiao, Qingang Wu, Ying Meng, Guijun Liu, Zheng Wang, Xueli Bai, Shengzhong Duan, Yuan Ding, Yanli Bi, Yuhao Wang, Gaopeng Li, Xiaoguang Liu, Zhimin Lu, Xiaohong Wu, Zhiyuan Tang, Daqian Xu   +35 more
openaire   +2 more sources